Mackay Shields LLC Biomarin Pharmaceutical Inc Transaction History

Mackay Shields LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 04, 2020	SELL	$71.87 - $131.03 $136,337 - $248,563	-1,897 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$79.55 - $124.22 $39,775 - $62,110	-500 Reduced 20.86%	1,897 $234,000
Q1 2020 May 08, 2020	SELL	$71.37 - $96.85 $71,370 - $96,850	-1,000 Reduced 29.44%	2,397 $203,000
Q4 2019 Feb 11, 2020	SELL	$64.27 - $86.37 $57,843 - $77,733	-900 Reduced 20.94%	3,397 $288,000
Q3 2019 Nov 01, 2019	BUY	$67.4 - $85.11 $67,400 - $85,110	1,000 Added 30.33%	4,297 $290,000
Q2 2019 Aug 13, 2019	SELL	$80.35 - $93.9 $2.4 Million - $2.8 Million	-29,825 Reduced 90.05%	3,297 $283,000
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $4.21 Billion - $4.93 Billion	-49,962,000 Reduced 99.93%	33,122 $2.94 Million
Q1 2019 May 13, 2019	BUY	$84.2 - $98.62 $4.21 Billion - $4.93 Billion	49,954,099 Added 121770.96%	49,995,122 $54.4 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $3.29 Million - $4.35 Million	41,023 New	41,023 $3.49 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.